Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Omni Nutraceuticals

This article was originally published in The Tan Sheet

Executive Summary

Company offers to delete statement "Healthy long-term joint support" from Inholtra Joint Pain, Joint Pain Plus dietary supplement/OTC combo products "if necessary to resolve all issues raised" by FDA, firm tells agency in Feb. 13 letter. Omni also says "active/inactive" distinction FDA made in its Feb. 8 letter is invalid because DSHEA authorizes use of supplements intended to affect structure, function of the body "without subjecting them to regulation as drug ingredients" (1"The Tan Sheet" Feb 18, 2002, p. 7). Company notes it "remains willing to meet with FDA to resolve outstanding issues"...

You may also be interested in...

B.F. Ascher Halts Supplement/OTC Combo Sales Following FDA Warnings

B.F. Ascher has discontinued the sale of its Melagesic PM dietary supplement/OTC combination in response to FDA's decision the product is an unapproved new drug, according to the agency

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts